Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Marja T. Nevalainen MD, PhD
Assistant Dean, Professor
Department of Pathology
Division of Administration

OFFICE ADDRESS:
Translational and Biomedical Research Center
8701 Watertown Plank Rd
Milwaukee, WI 53226
Phone: 414-955-2103
Fax: (414) 955-6059
Email: mnevalainen@mcw.edu

EDUCATION:
1985 - 1992 MD, University of Turku, School of Medicine, Turku, Finland.
1993 - 1997 PhD, University of Turku, School of Medicine, Department of Cell Biology, Turku, Finland.

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
1993 - 1994 Resident in Medicine, Primary Care Unit, Loimaa Regional Hospital, Loimaa, Finland.
1997 - 1998 Finnish Academy of Science Visiting Fellow, Uniformed Services University of the Health Sciences, US Military Cancer Institute, Bethesda, MD
1998 - 1999 WHO-IARC-Fellow (World Health Organization's International Agency for Research on Cancer), Uniformed Services University of the Health Sciences, US Military Cancer Institute, Bethesda, MD

FACULTY APPOINTMENTS:
1994 - 1997 Instructor, Department of Anatomy and Cell Biology, Institute of Biomedicine, University of Turku, Turku, Finland.
2002 - 2003 Assistant Professor, Department of Cell Biology and Department of Oncology, Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC.
2003 - 2006 Assistant Professor, Department of Oncology, Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC.
2006 - 2015 Associate Professor, Department of Cancer Biology, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
2006 - 2015 Associate Professor, Department of Medical Oncology, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
2007 - 2015 Associate Director of Education, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
2008 - 2015 Vice Chair of Education, Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA
2009 - 2015 Associate Director, Greater Philadelphia Prostate Cancer Working Group, Department of Urology, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
2009 - 2015 Associate Professor, Department of Urology, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
2015 - Present Professor, Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI
2015 - Present Professor, Pathology, Medical College of Wisconsin, Milwaukee, WI
2015 - Present Associate Director of Education, Cancer Center, Medical College of Wisconsin, Milwaukee, WI
2015 Co-Director, PhD Program: Genetic, Genomic and Cancer Biology, Thomas Jefferson University, Philadelphia, PA
2017 - Present Assistant Dean of Research, Medical College of Wisconsin, Milwaukee, WI
2017 - Present Director, Prostate Cancer Center of Excellence, Medical College of Wisconsin, Milwaukee, WI
2017 - Present Eminent Scholar, Medical College of Wisconsin, Milwaukee, WI

ADMINISTRATIVE APPOINTMENTS:
2007 - 2015 Member, Executive Committee, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
2008 - 2015 Vice Chair (Education), Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA
2015 - Present Member, Executive Committee, Cancer Center, Medical College of Wisconsin, Milwaukee, WI
2016 - Present Member, Director's Council, MCW Cancer Center, Medical College of Wisconsin, Milwaukee, WI

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:
2007 - 2015 Associate Director of Education, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
2014 - 2015 Co-Director of Genetic, Genomic and Cancer Biology PhD Program, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
2015 - Present Associate Director of Education, Cancer Center, Medical College of Wisconsin, Milwaukee, WI
2016 - Present Chair, Education & Training Committee, Cancer Center, Medical College of Wisconsin, Milwaukee, WI
2016 - Present Chair, Graduate Course development committee, Medical College of Wisconsin, Milwaukee, WI

RESEARCH ADMINISTRATIVE APPOINTMENTS:
2009 - 2015 Associate Director, Greater Philadelphia Prostate Cancer Working Group, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
2016 - Present Director, Prostate Cancer Working Group, Medical College of Wisconsin, Milwaukee, WI
2017 - Present Assistant Dean of Research, Medical College of Wisconsin, Milwaukee, WI
2017 - Present Eminent Scholar, Medical College of Wisconsin, Milwaukee, WI
2017 - Present Director, Prostate Cancer Center of Excellence, Medical College of Wisconsin, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:
Licensure
Number Issue DateExpiration
Medical
SV302216SF
09/02/1993
None
 

AWARDS AND HONORS:
1989 The Arvo and Inkeri Suominen Foundation; FIM 8,000. Criteria: Project merit, scientific and educational achievements.
1989 The Ida Varpu Parte Cancer Foundation; FIM 1,670. Criteria: Project merit, scientific and educational achievements.
1989 The Finnish Cultural Foundation (South-Finland Dept.); FIM 10,000. Criteria: Project merit, scientific and educational achievements.
1990 The City of Turku; FIM 10,000. Criteria: Project merit, scientific and educational achievements.
1990 The Finnish-Norwegian Foundation of Medical Science; FIM 10,000. Criteria: Project merit, scientific and educational achievements.
1992 The Ida Montin Foundation; FIM 10,000. Criteria: Project merit, scientific and educational achievements.
1992 - 1990 The Emil and Blinda Maunula Foundation; FIM 8,000. Criteria: Project merit, scientific and educational achievements.
1993 The Cancer Society of South-Western Finland; FIM 17,500. Criteria: Project merit, scientific and educational achievements.
1993 The Cancer Societies of Finland; FIM 15,500. Criteria: Project merit, scientific and educational achievements.
1993 The Finnish Endocrine Society; FIM 5,000. Criteria: Project merit, scientific and educational achievements.
1993 Award of 5,000 FIM for the best scientific presentation (oral communication) in the Annual Meeting of the Endocrine Society of Finland, May 6-8. "Hormone Regulation of Human Prostate in Organ Culture, Endocrine Society of Finland.
1994 The Finnish Medical Foundation and Duodecim (Finnish College of Physicians); FIM 15,000. Criteria: Project merit, scientific and educational achievements.
1994 The Finnish Academy; FIM 4,600, Travel stipend.
1994 Invited Plenary lecture: Gordon Research Conference on Prolactin, Oxnard, CA.
1995 The University Foundation of Turku; FIM 6,000. Criteria: Project merit, scientific and educational achievements.
1996 The Finnish Medical Foundation and Duodecim (Finnish College of Physicians); FIM 15,000. Criteria: Project merit, scientific and educational achievements.
1996 Award of 5,000 FIM for the best scientific presentation (oral communication) in the Annual Meeting of the Finnish Endocrine Society, April 25-26. , “Prolactin as a death antagonist of rat dorsolateral prostate in organ culture”. PM. Martikainen, TJ. Ahonen, J. Laine, P. Härkönen, MT. Nevalainen.
1997 The University of Turku, Rockefeller Foundation; FIM 6,000. Criteria: Project merit, scientific and educational achievements.
1997 Nomination for the best PhD-thesis of the year 1997 at the University of Turku, School of Medicine: MT. Nevalainen: “Prolactin Regulation of Rat and Human Prostate”, Thesis defense, 30 May., Thesis supervisor: Professor Pirkko Harkonen, reviewed by Professor Pekka Leinonen (Univ. Helsinki), Professor Jorma Isola (Univ. Tampere) and by Professor Olli Janne (Univ. Helsinki).
2000 Invited Plenary lecture: Gordon Research Conference on Prolactin, Ventura, CA.
2004 Certificate for Excellence in Research for Outstanding Performance and Contributions, Lombardi Comprehensive Cancer Center, Georgetown University, June 28.
2004 American Cancer Society Research Scholar, July 1.
2004 Invited Plenary lecture: Gordon Research Conference on Prolactin, Ventura, CA.
2005 Distinguished Lecturer, Department of Defense Center for Prostate Disease Research, Rockville, MD. February 9.
2005 Invited: Thesis Examiner/Faculty Opponent: Nina Ohlson, PhD-thesis. Early Effects of Castration Therapy in Non-malignant and Malignant Prostate Tissue. , Thesis Advisors: Anders Bergh, MD, PhD, Pernilla Wickstrom, PhD. Umea University, Department of Medical Biosciences, Pathology, Department of Surgical Sciences, Urology, Umea, Sweden.
2006 - 2010 Member of the Integration Panel: Congressionally Directed Medical Research Programs of Department of Defense: Prostate Cancer Program Programmatic Review, Virginia.
2007 - 2015 Member, Executive Committee of Sidney Kimmel Cancer Center.
2007 The Thomas Jefferson University Faculty Research Performance Award.
2008 Session Chair: "Lennox K. Black International Prize for Excellence in Biomedical Research, 5th Symposium, "Transformational Discoveries in Cancer." Philadelphia, PA.
2008 Award for Distinguished Mentor Nomination, Thomas Jefferson University.
2009 Postdoctoral Travel Fellowship Award from the Society of Basic Urological Research: Zhiyong Liao, PhD - attendance at SBUR meeting 2009, Nevalainen Laboratory.
2009 Postdoctoral Travel Fellowship Award from Thomas Jefferson University: Viviana Vogiatzi, MD, PhD - attendance at SBUR meeting 2009, Nevalainen Laboratory.
2009 Recognition Award for Participating in the Scientific and Clinical Update on Prostate Cancer, Thomas Jefferson University.
2009 - 2010 Member of the University Research Advisory Committee, (Chair: Vice President of Research; Dr. Steven McKenzie), Thomas Jefferson University.
2009 Invited Plenary lecture: Gordon Research Conference; Hormone Action in Development and Cancer, Plymouth, NH.
2010 Invited Plenary Lecture: 19th Meeting of European Association of Urological Research (ESUR), Vilnius, Lithuania.
2010 Session Chair: 19th Meeting of the European Association of Urological Research, Vilnius, Lithuania.
2011 - 2015 Member of the Dean's Jefferson Medical College Research Leadership Council, Thomas Jefferson University.
2011 Certificate of Appreciation in Grateful Recognition of Outstanding Service to Kimmel Cancer Center at Thomas Jefferson University, April 2011.
2012 David Hoang, MD-PhD-Student: The Endocrine Society Travel Award. Oral Presentation, The GH/PRL Family in Biology and Disease, FASEB Science Research Conference, Silvertree Hotel, Snowmass, CO, Jul. 11, Nevalainen Laboratory.
2012 David Hoang, MD-PhD-Student: Sigma Xi Student Research Day, Award Winner: M.D./Ph.D. Category, Poster Presentation, 2012 Poster Presentation, Sigma Xi Student Research Day, Thomas Jefferson Universit, Nevalainen Laboratory.
2012 Invited Plenary Lecture: Annual Meeting of the Endocrine Society 2012, Houston, TX.
2012 Jefferson Medical College Dean's Award for Faculty Mentoring, April 2012.
2012 David Hoang, MD-PhD-Student: Jefferson Graduate School of Biomedical Sciences Alumni Association Travel Fellowship. Oral Presentation, The GH/PRL Family in Biology and Disease, FASEB Science Research, Nevalainen Laboratory.
2012 Invited Plenary Lecture: FASEB Summer Research Conference: The Growth Hormone/Prolactin, Snowmass, CO.
2012 Pooja Talati, PhD-Student, Pre-doctoral Travel Fellowship from Thomas Jefferson University - attendance at the FASEB meeting, Nevalainen Laboratory.
2012 Session Chair: FASEB Summer Research Conference: The Growth Hormone/Prolactin, Snowmass, CO.
2013 - 2015 Member of the Integration Panel: Congressionally Directed Medical Research Programs of Department of Defense: Prostate Cancer Program Programmatic Review, Virginia.
2013 David Hoang, MD-PhD-Student: Sigma Xi Grant-In-Aid of Research. Title: Targeting Stat5a/b signaling in prostate cancer stem cells to eliminate growth of castrate-resistant prostate cancer, Nevalainen Laboratory.
2013 David Hoang, MD-PhD-Student (PI: Nevalainen): F31 NCI Fellowship Award, funded.
2013 Pooja Talati, PhD-Student, Frederic Rieders Family Renaissance Foundation Graduate Student Recognition Award, Nevalainen Laboratory.
2014 Discovery of the Year Award (Development of Small-Molecule Stat5a/b Inhibitors); Sidney Kimmel Cancer Center, Thomas Jefferson University.
2014 Invited Plenary Lecture: GRS-IGF Society Meeting, Singapore.
2015 Invited Plenary Lecture: International Conference in Cytokine Signaling in Cancer, Crete, Greece.
2015 Invited attendee to the Prostate Cancer Foundation (PCF) Annual Scientific Retreat (by invitation only), Prostate Cancer Foundation, Washington DC, October 2015.
2015 Session Chair. FASEB meeting, The GH/Prl Family in Biology and Disease. Steamboat, CO.
2016 Invited member of Panel discussion on Personalized Medicine in Prostate Cancer Management., Society for Basic Urological Research (SBUR) Fall Symposium, Fort Lauderdale FL, November 2016.
2016 Senior Editor's Meeting at Elsevier headquarters, International Journal of Biochemistry and Cell Biology, Amsterdam, Netherlands, October 2016.
2016 Invited attendee to the Prostate Cancer Foundation Annual Scientific Retreat (by invitation only) and Women's Forum held in conjunction with retreat., Prostate Cancer Foundation, Carlsbad, CA, October 2016.
2017 Invited Speaker: FASEB meeting, The GH/Prl Family in Biology and Disease, Steamboat Springs, CO, July 2017.
2017 Invited attendee to Prostate Cancer Foundation Annual Scientific Retreat (by invitation only), Prostate Cancer Foundation, Washington, DC, October 2017.
2017 Senior Editor's meeting at Elsevier headquarters., International Journal of Biochemistry and Cell Biology, Amsterdam, Netherlands, October 2017.

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
1988 - 1997 Finnish Endocrine Society
1990 - Present Duodecim (Finnish College of Physicians)
1991 - 1997 Turku Cancer Scientist Association
1994 - Present American Association for the Advancement of Science
1999 - Present Endocrine Society
1999 - Present American Association for Cancer Research
1999 - 2005 International Cytokine Society
2006 - Present American Association of Investigative Pathology

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Editorship
2006 -"Prostate Cancer: Signaling Networks, Genetics and New Treatment Strategies", Humana Press, Editors: Marja T. Nevalainen, Richard G. Pestell.
2009 - Present International Journal of Biochemistry and Cell Biology, The US Senior Editor.
Editorial Board
2008 - Present American Journal of Pathology, Member of the Editorial Board.
2010 - Present International Journal of Clinical and Experimental Pathology, Member of the Senior Editorial Board.
2010 - Present Research and Reports in Biology, Member of the Honorary Editorial Board.
2011 - Present World Journal of Methodology, Member of the Editorial Board.
2012 - Present The Prostate, Member of the Editorial Board.
2012 - Present Journal of Integrative Oncology, Member of the Editorial Board.
Journal Review
Oncogene
Gene
Molecular Cellular Biology
Faseb Journal
Cytokine
Biochemistry
Journal of Biological Chemistry
Clinical Cancer Research
Cancer Research
International Journal of Biochemistry and Cell Biology
Molecular Endocrinology
Journal of Molecular Endocrinology and Metabolism
Nature Endocrinology and Metabolism
Endocrine Reviews
International Journal of Cancer
American Journal of Pathology
Endocrinology
Molecular and Cellular Endocrinology
Breast Cancer Research
Cancer Chemotherapy and Pharmacology
Endocrine-Related Cancer
Anatomical Record
Laboratory Investigations
The Prostate
Journal of Andrology
Journal of Medicinal Chemistry
European Journal of Endocrinology

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
2004 - 2006 Member, Tumor Biology Graduate Program, Oversight Committee, Georgetown University, Dept. of Oncology.
2004 - 2006 Member, PhD Thesis Committee for Angele Nalbandian, Georgetown University, Dept. of Cell Biology.
2005 - 2006 Member, PhD Thesis Committee for Anne Miermont, Georgetown University, Dept. of Oncology.
2005 - 2006 Course Co-Director, Tumor Biology Graduate Program, Cancer Research Data Meetings, Georgetown University.
2006 - 2015 Member, Committee on Research, Thomas Jefferson University.
2006 - 2011 Chair, Training and Seminar Organization, Prostate Cancer Training and Seminars, Sidney Kimmel Cancer Center, Dept of Urology, Thomas Jefferson University.
2007 - 2015 Member, Oversight Committee for Small Molecular Screening, Sidney Kimmel Cancer Center, Thomas Jefferson University.
2007 - 2014 Chair, Kimmel Cancer Center Training Committee, Sidney Kimmel Cancer Center, Thomas Jefferson University.
2007 - 2015 Member, Sidney Kimmel Cancer Center, Executive Committee.
2007 - 2015 Associate Director of Education, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
2008 - Member, Symposium Organization, Prostate Cancer Symposium, "Spirit of Courage", Keynote speaker Mike Milken, Prostate Cancer Foundation, Thomas Jefferson University.
2008 - Session Chair, Symposium Organization, Lennox K. Black International Prize for Excellence in Biomedical Research, 5th Symposium, "Transformational Discoveries in Cancer", Thomas Jefferson University, Philadelphia PA.
2008 - 2011 Organizer and Host, Symposium Organization, America Cancer Society Institutional Research Grant Symposium, Sidney Kimmel Cancer Center, Thomas Jefferson University.
2008 - 2010 Member, Professorial Faculty Advisory Committee, Thomas Jefferson University.
2008 - 2012 Member, PhD Thesis Committee of Xiang Wang, PI:Linda Siracusa, Thomas Jefferson University.
2008 - 2015 Vice Chair of Education, Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA.
2009 - Organizer and Host, Giacchino Lecture Series, Sidney Kimmel Cancer Center: Speaker Owen Witte, MD, Howard Hughes Medical Institute, University of California, "Prostate Stem Cells and Cancer Progression", Thomas Jefferson University.
2009 - 2010 Member, PhD Thesis Committee of Ankur Sharma, PI: Karen Knudsen, Thomas Jefferson University.
2009 - 2010 Member, Research Advisory Committee (Chair: Vice President of Research, Dr. Steven McKenzie), Thomas Jefferson University.
2009 - 2015 Associate Director, Greater Philadelphia Prostate Cancer Working Group, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA.
2009 - 2010 Member, Dean's Faculty Forward Task Force, Thomas Jefferson University.
2009 - 2012 Member, PhD Thesis Committee of Supriya Shah, PI: Karen Knudsen, Thomas Jefferson University.
2009 - 2015 Member, PhD Thesis Committee of Michael Augello, Biochemistry and Molecular Pharmacology Program, PI: Karen Knudsen, Thomas Jefferson University.
2010 - 2015 Mentor: Pooja Talati, PhD student, Molecular Pharmacology and Structural Biology Program, Thomas Jefferson University.
2010 - 2015 Member, PhD Thesis Committee of Michael Augello, PI: Karen Knudsen, Thomas Jefferson University.
2010 - 2015 Mentor: David Hoang, MD,PhD student, Molecular Pharmacology and Structural Biology Program, David Hoang: Graduated August 15, Thomas Jefferson University.
2010 - Organizer and Host, Giacchino Lecture Series, Sidney Kimmel Cancer Center: Speaker William Kaelin MD, Professor, Dept of Medicine at Harvard Medical School. Thomas Jefferson University.
2011 - Organizer and Host, Symposium Organizer, The Greater Philadelphia Prostate Cancer Working Group Trainee Symposium, Keynote Speaker Edward Gelman, University of Columbia, NY.
2011 - Organizer and Host, Giacchino Lecture Series, Sidney Kimmel Cancer Center: Speaker Charles Sawyer MD, Chair of Human Oncology and Pathogenesis Program, Howard Hughes Medical Institute and Memorial Sloan Kettering Cancer Center. Thomas Jefferson University.
2011 - 2015 Member, Dean's Research Leader's Council, Thomas Jefferson University.
2012 - 2013 Member, Faculty Senate, Thomas Jefferson University.
2012 - 2015 Member, Genomics Steering Committee, Genetics and Cancer Biology Graduate Program., Sidney Kimmel Cancer Center, Thomas Jefferson University.
2013 - 2015 Member, PhD Thesis Committee of Amrita Singh; Biochemistry and Molecular Pharmacology Program, PI: Lucia Languino, Thomas Jefferson University.
2013 - 2015 Member, PhD Thesis Committee of Carmella Romeo; Cell and Developmental Biology Program, PI: Jonathan Brody, Thomas Jefferson University.
2015 - Present Member, Cancer Center Executive Committee, Medical College of Wisconsin
2015 - Present Associate Director of Education, Cancer Center, Medical College of Wisconsin, Milwaukee, WI.
2015 Co-Director, PhD Program-Genetic, Genomic and Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
2016 - Present Member, Cancer Center Director's Council, Medical College of Wisconsin
2016 - Present Director, Prostate Cancer Working Group, Medical College of Wisconsin Cancer Center
06/01/2017 - Present Invited member, Internal Advisory Board, Center for Biomedical Mass Spectrometry Research, MCW

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
2006 - 2010 Integration Panel, Congressionally Directed Medical Research Programs of Department of Defense, Prostate Cancer Program Programmatic Review, Virginia.
2012 Session Chair, FASEB Summer Research Conference, The Growth Hormone/Prolactin, Snowmass, CO.
2013 - 2015 Integration Panel, Congressionally Directed Medical Research Programs of Department of Defense, Prostate Cancer Program Programmatic Review, Virginia.
07/19/2015 - 07/24/2015 Session Chair, FASEB meeting, The Growth Hormone/Prolactin Family in Biology and Disease. Steamboat, CO.
2016 - Present Invited member, Panel Discussion on Personalized Medicine in Prostate Cancer Management, Society for Basic Urological Research (SBUR) Fall Symposium

COMMUNITY SERVICE ACTIVITIES:
10/29/2015 Community event: attendance to the 2015 Wisconsin Breast Cancer Showhouse recognition dinner at the Town Club in Fox Point, WI
02/09/2016 Educational event: M1 M2 Annual dinner for medical students to network and interacting with faculty. "Eye on the future: Making the most of the next steps in your Medical career."
03/22/2016 Community event: Milwaukee Area Pathologist Spring meeting and dinner, with speaker John Cheville, MD of Mayo Clinic.
 

ADVISOR:
1999 - 2005 MD, PhD Student: Tommi Ahonen, “Characterization of Stat5-dependent survival of prostate cancer cells”,Georgetown University; Thesis Mentor: Marja T. Nevalainen. Graduated August 12, 2005.
2002 - 2004 Post-Doctoral Fellow: HongZhen Li, MD, PhD. Dept. of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University.
2002 - Medical Student: Rita Kralik, MD. PhD-Graduate-Student, Dept. of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University.
2003 - 2006 Post-Doctoral Fellow: Ayush Dagvadorj, MD, PhD. Dept. of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University.
2004 - 2007 Post-Doctoral Fellow: Junaid Abdulghani, MD, PhD. Dept. of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University and Dept. of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University.
2004 - 2005 Radiation Oncology Fellow: Sean P. Collins, MD, PhD, Dept. of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University.
2005 - 2006 Research Assistant: Munkhtsegtseg Dorg, MD. Research Assistant, Dept. of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University.
2005 - 2006 Post-Doctoral Fellow: Shyh-Han Tan, PhD, Post-Doctoral Fellow, Dept. of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University.
2005 - Graduation Rotation Student: Shane Vincent Formica, PhD-Graduate student (Tumor Biology Program), Dept. of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University.
2005 - Graduate Rotation Student: Elspeth Beauschamp, PhD-Graduate student (Tumor Biology Program), Laboratory Rotation, Dept. of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University.
2005 - Graduate Rotation Student: Randy Lee King, PhD-Graduate student (Tumor Biology Program), Dept. of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University.
2006 - 2010 Research Associate: Ayush Dagvadorj, MD, PhD. Research Associate, Dept. of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University.
2006 - 2012 Research Associate: Zhiyong Liao, PhD, Research Associate, Sidney Kimmel Cancer Center, Thomas Jefferson University.
2006 - 2010 Research Assistant: Jacqueline Lutz, MS. Research Assistant, Dept. of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University.
2006 - 2007 Research Associate: Shyh-Han Tan, PhD, Research Associate, Dept. of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University.
2007 - 2008 Post-Doctoral Fellow: Lei Gu, MD, Dept. of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University.
2008 - 2009 Post-Doctoral Fellow: Ana Romero-Weaver, PhD. Dept. of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University.
2008 - PhD Visiting Student: Martin Puhr, MS, Graduate Student Rotation (6 months) in Dr. Nevalainen’s Laboratory. Univ. of Innsbruck, Austria.
2008 - 2015 Research Associate: Lei Gu, MD, Research Associate, Dept. of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University.
2008 - 2010 Post-Doctoral Fellow: Paraskevi Viviana Vogiatzi, MD, PhD. Dept. of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University.
2009 - 2011 Post-Doctoral Fellow: Mateusz Koptyra, PhD, Dept. of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University.
2009 - 2010 Medical Student: Andrzej Wojcieszynski,Thomas Jefferson University.
2009 - 2011 Medical Oncology Fellow: Shilpa Gupta, MD. Medical Oncology Fellow, Thomas Jefferson University.
2009 - 2010 Medical Student: Anita Mamtani, Thomas Jefferson University.
05/2010 - 09/2010 Visiting Scientist: Tuomas Mirtti, MD, PhD. Pathologist. University of Helsinki, Helsinki, Finland.
2010 - 2012 Instructor: Ayush Dagvadorj, MD, PhD. Research Instructor, Dept. of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University.
2010 - 2015 Research Assistant: Elyse Ellsworth, BS. Research Assistant, Dept. of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University.
2010 - Graduation Rotation Student: David Hoang. MD-PhD-student, Molecular Pharmacology and Structural Biology Program; Thomas Jefferson University.
2010 - Graduation Rotation Student: Pooja Talati, Molecular Pharmacology and Structural Biology Program; Thomas Jefferson University.
2010 - 2014 PhD and MD, PhD Student: David Hoang. Molecular Pharmacology and Structural Biology Program. Graduated August 15, 2014. Thesis Mentor: Marja T. Nevalainen.
2010 - 2015 PhD Student: Pooja Talati. Molecular Pharmacology and Structural Biology Program, Thomas Jefferson University.Thesis Mentor: Marja T. Nevalainen.
2011 - 2013 Master's Student: Shauna Blackmon, Master’s Program in Cell and Developmental Biology, Thomas Jefferson University. “Regulation of prostate cancer growth in vivo and ex vivo by pharmacological inhibition of Stat5 signaling”, Graduated Dec. 19th, 2013. Master’s Thesis Mentor: Marja T. Nevalainen.
2013 - 2015 Post-Doctoral Fellow: Elizabeth Marek, PharmD, Dept. of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University.
2015 - Graduation Rotation Student: Yaoming Yaing, PhD-Graduate student (Molecular Pharmacology and Structural Biology Program), Laboratory Rotation, Dept. of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University.
2015 - Present Research Assistant, Harmanjot Singh, BS, Department of Pathology, Medical College of Wisconsin.
2015 - Present Post-Doctoral Fellow: Sara Schmitt, PhD, Department of Pathology, Medical College of Wisconsin.
2015 - Present Post-Doctoral Fellow; Vindhya Udhane, PhD, Department of Pathology, Medical College of Wisconsin.

ASSOCIATE DIRECTOR OF EDUCATION RESPONSIBILITES:
2008 - 2015 At Sidney Kimmel Cancer Center, oversaw the Mentoring Program of Junior Faculty in Cancer Research at Thomas Jefferson University, sponsored by the American Cancer Society. Oversaw American Cancer Society Institutional Research Grant (ACS-IRG; Nevalainen – Co-PI, Pestell – PI), including solicitation of the annual funding announcements, chair the review panel meeting for the seed funding applications annually, chair the annual American Cancer Society Symposium at the Kimmel Cancer Center, chair the Annual luncheon for the new awardees with the representatives of the local ACS office, annual ACS-IRG grant reports, submissions of the competitive ACS-IRG grant renewals. This ACS-IRG-funded Mentoring Program of Junior Faculty in Cancer Research at Thomas Jefferson University has provided seed grants (15-30K) to 19 applicants to date resulting in more than 17 national peer reviewed grants totaling in more than 5 million in grant revenues to Thomas Jefferson University.
2014 - 2015 Development of the educational activities of Sidney Kimmel Cancer Center at Thomas Jefferson University for the application of Comprehensive Cancer Center status.
- At Sidney Kimmel Cancer Center, Thomas Jefferson University: Oversight of the Graduate Cancer Center-related Programs.
- At Sidney Kimmel Cancer Center, Thomas Jefferson University: Chair of the Training Committee of the Graduate Programs.
- At Sidney Kimmel Cancer Center, Thomas Jefferson University: Maintained the Cancer Center Education websites.
- At Sidney Kimmel Cancer Center, Thomas Jefferson University: Organize and chair the Greater Philadelphia Prostate Cancer Working Group Annual Prostate Trainee Symposium.
- At Sidney Kimmel Cancer Center, Thomas Jefferson University: Oversight of the Medical Oncology and Radiation Oncology Fellowship programs (Basic Cancer Research Training).
- At Sidney Kimmel Cancer Center, Thomas Jefferson University: Oversight of the weekly Graduate Program “Research in Progress” seminars.

INTERNATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSTIONS:
1999 - 2005 Thesis Mentor: MD-PhD-Thesis: Tommi Ahonen, Title: "Characterization of Stat5-dependent Survival of prostate Cancer Cells". Institute of Biomedicine, University of Turku, Turku, Finland.
2005 Committee-nominated Thesis Opponent for PhD Thesis of Nina Ohlson titled "Early Effects of Castration Therapy in Non-malignant and Malignant Prostrate Tissue". Thesis advisors: Anders Bergh, MD, PhD; Pernilla Wickstrom, PhD. Umea University, Dept. of Medical Biosciences, Pathology, Dept. of Surgical Sciences, Urology, Umea, Sweden. Invitation to this academic service was based on special expertise in the research field.
2010 Session Chair: 19th Meeting of the European Association of Urological Research (ESUR), October 7-9, 2010, Vilnius, Lithuania.
2011 Committee-nominated Reviewer: MD-PhD-Thesis; Paula Vainio. Title: High-Throughput Screening for Novel Prostate Cancer Drug Targets. Thesis Advisors: Olli-Pekka Kallioniemi, MD, PhD; Kristiina Iljin, PhD. University of Turku, Turku Centr of Biotechnology and University of Helsinki, Finland Institute for Molecular Medicine (FIMM).
2012 Session Chair: FASEB Summer Research Conference: The Growth Hormone/Prolactin, Snowmass, CO.
2012 Committee-nominated Reviewer: PhD-Thesis; Biswasjyoti Sahu. Title: Genome-wide Analysis of Androgen Receptor Function in Prostate Cancer. Thesis Advisor: Olli Janne, MD, PhD. University of Helsinki, Institute of Biomedicine, Graduate Program in Biotechnology and Molecular Biology.
2015 Session Chair. FASEB meeting, The GH/Prl Family in Biology and Disease. Steamboat, CO.

LECTURES BY INVITATION:
1992 "The Expression of Prolactin Receptor mRNA in Dorsal and Lateral Lobes of the Rat Prostate". Annual Meeting of the Endocrine Society of Finland, University of Turku, Finland (April 3-4, 1992).
1993 "Estrogen and Prolactin Regulation of Prostate in Organ Culture". Symposium of the Regulation of Prostate Growth. Experimental Basis and Clinical Applications. University of Turku, Turku, Finland (September 6-7, 1993).
1993 "Hormone Regulation of Human Prostate in Organ Culture". Annual Meeting of the Endocrine Society of Finland, University of Turku, Finland (May 6-8, 1993).
1994 "Androgen-Independent Effects of Prolactin on Prostatic Cells". Gordon Research Conference on Prolactin, Oxnard, CA (January 31-February 4, 1994).
1997 "Prolactin as a death antagonist of rat dorsolateral prostate in organ culture". Annual Meeting of the Finnish Endocrine Society (April 25-26, 1997).
2000 "Prolactin is a survival factor in androgen-deprived rat dorsal and lateral prostate in organ culture". Gordon Research Conference on Prolactin,Ventura, CA (January 30-February 4, 2000).
2002 "Targeting Signaling Pathways of Prolactin, A Local Growth Factor for Prostate Epithelium". Departmental Seminar, Dept. of Cell Biology, Georgetown University (June 6, 2002).
2002 "Prolactin, A Local Growth Factor for Prostate Epithelium". Prostate Cancer Data Meeting, Dept. of Cell Biology, Georgetown University (May 15, 2002).
2003 "Inhibition of Transcription Factor Stat5 in Human Prostate Cancer". Prostate Cancer Meeting, Dept. of Cell Biology, Georgetown University (February 5, 2003).
2003 "Targeting Signaling Pathways of Prolactin, a Local Growth Factor for Prostate Epithelium". Departmental Seminar, Dept. of Pathology, Uniformed Services University of Health Sciences, Bethesda, MD (April, 25, 2003).
2004 “PRL/Stat5 System Regulating Prostate Cell Survival”. Institutional seminar series, Institute of Medical Technology (IMT), University of Tampere, Tampere, Finland (March 15, 2004).
2004 “Transcription Factor Stat5 as a Potential Therapeutic Target Protein in Human Prostate Cancer”. Molecular Therapeutics Data Meeting, Lombardi Comprehensive Cancer Center Georgetown University (April 20, 2004).
2004 “Therapy Development for Prostate Cancer”. Brown Bag Seminar Series, Lombardi Comprehensive Cancer Center, Georgetown University (July 14, 2004).
2004 “Transcription Factor Stat5 as a Critical Survival Factor in Human Prostate Cancer”, American Cancer Society Mini-symposium, Lombardi Comprehensive Cancer Center (September 3, 2004).
2004 “PRL/Stat5 System Regulating Prostate Cell Survival”. Gordon Conference on Prolactin, Ventura, CA (February 1-6, 2004).
2004 “Transcription Factor Stat5 as a Survival Factor in Human Prostate Cancer”. Cancer Research Meeting, Lombardi Comprehensive Cancer Center, Georgetown University (April 8, 2004).
2004 “Transcription Factor Stat5 as a Survival Factor in Human Prostate Cancer”. Institutional seminar series: Center for Reproductive and Developmental Medicine (CREDE), Institute of Biomedicine, University of Turku, Turku, Finland (March 19, 2004).
2005 “Transcription Factor Stat5 in Growth and Progression of Prostate Cancer”, Prostate Cancer Data Meeting, Dept. of Cell Biology, Georgetown University (February 9, 2005).
2005 “Transcription Factor Stat5 in Growth and Progression of Prostate Cancer”, Dept. of Defense, Center for Prostate Disease Research (CPDR), Rockville, MD (February 2, 2005).
2005 “Identification of Molecular Targets for Prostate Cancer Therapy Development”, Umea University, Institute of Biomedicine, Umea, Sweden, (December 15, 2005).
2005 “Transcription Factor Stat5 Provides a Survival Signal for Prostate Cancer Cells during Androgen Deprivation”, American Cancer Society 2005 Professors Meeting: Leading the Way: 60 Years of American Cancer Society Researchers, Miami, FL (November 2-5, 2005).
2005 “Transcription Factor Stat5 as Target for Therapy Development for Prostate Cancer”, Georgetown University, Board of Regents, Research Committee: “Cutting Edge Science from Georgetown University” (October 28, 2005).
2006 “Interaction between Stat5 and Androgen Receptor Signaling in Prostate Cancer”, Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, (December 18, 2006).
2006 “Stat Transcription Factors in Progression of Prostate Cancer”, Kimmel Cancer Center Seminar Series, Thomas Jefferson University, (October 9, 2006).
2006 “Molecular Interaction between Androgen Receptor and Transcription Factor Stat5 in Mediation of Androgen-Independent Growth of Prostate Cancer”, Department of Urology, Innsbruck Medical University, Innsbruck, Austria, (September 4, 2006).
2007 “Jak-Stat Signaling Provides Molecular Targets for Therapy Development for Hormone Refractory Prostate Cancer”, University of Nebraska Medical Center, Eppley Institute for Cancer Research, Omaha, NE (April 26, 2007).
2007 "Transcription Factor Stat5 in Progression of Prostate Cancer to Advanced Disease and as a Therapeutic Target Protein for Prostate Cancer", Innovative Minds in Prostate Cancer Today (IMPaCT); (Congressionally Directed Medical Research Programs of Department of Defense), Atlanta, GA (September 5-8, 2007).
2007 “Stat5 in Urogenital Cancers’, Research Seminar, Center for Molecular Studies in Digestive and Liver Disease, University of Pennsylvania, (November 15, 2007).
2007 “Activation of Transcription Factor Stat5 and Prostate Cancer Prognosis”,The 14th International AEK Cancer Congress, Cancer Society of Germany (Deutsche Krebsgesellschaft) (February 28-March 2, 2007).
2008 “Transcription Factor Stat5 as a Therapeutic Target Protein for Recurrent Prostate Cancer”. Lankenau Institute of Medical Research, Wynnewood, PA (March 13, 2008).
2008 “Transcription Factor Stat 5: A Potential Sensitizer for Radiation-induced Prostate Cancer Cell Death”, Department of Radiation Oncology, Thomas Jefferson University (March 3, 2008).
2008 “Transcription Factor Stat5 Interaction with Androgen Receptor in Growth Promotion of Prostate Cancer”, University of Delaware, Wilmington, DE (May 7, 2008).
2008 “Transcription Factor Stat5a/b as a Determinant of Therapy Response of Prostate Cancer”. Oncology Grand Rounds, Kimmel Cancer Center, Thomas Jefferson University (November 19, 2008).
2008 “Transcription Factor Stat5a/b as a Therapeutic Target and a Determinant of Therapy Response of Prostate Cancer.” Grand Rounds, Department of Pathology, Thomas Jefferson University (February 18, 2008).
2008 “Transcription factor Stat5 interaction with androgen receptor in growth promotion of prostate cancer”, ABCAM Meeting – Nuclear Receptors: Co-Activators and Co-Repressors, National Constitution Center, Philadelphia, PA (January 15, 2008).
2008 “Stat Transcription Factors in Progression of Prostate Cancer to Hormone-Refractory and Metastatic Disease”, Department of Biochemistry, Dalhousie University, Halifax, Nova Scotia, Canada (February 7, 2008).
2008 “Transcription Factor Stat5 Interaction with Androgen Receptor in Growth Promotion of Prostate Cancer”, Fourth Annual National Symposium on Prostate Cancer, Clark-Atlanta University, Atlanta, GA (March 17-18, 2008).
2008 “Stat Transcription Factors as Therapeutic Target Proteins for Prostate Cancer.” Prostate Cancer Symposium: “Spirit of Courage”, Thomas Jefferson University (May 15, 2008).
2009 “Autocrine Prl-Jak2-Stat5 Pathway Promotes Growth and Progression of Prostate Cancer”. Gordon Conference; Hormone Action in Development and Cancer, Plymouth, NH (July 26-31, 2009).
2009 “Stat5 in Progression of Prostate Cancer and as a Target Protein for Therapy Development”. Columbia University, NewYork, NY (October 30, 2009).
2009 “Transcription Factor Stat5 as a Therapeutic Target Protein for Prostate Cancer.” Fifth Annual National Symposium on Prostate Cancer, Clark-Atlanta University, Atlanta, GA (March 15-17, 2009).
2009 "Transcription Factor Stat5a/b as a Therapeutic Target Protein for Prostate Cancer.” AstraZeneca, Waltham, MA (April 2-3, 2009).
2009 “Transcription Factor Stat5a/b as a Therapeutic Target Protein for Prostate Cancer”. Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA (October 14, 2009).
2009 “Stat5 in Prostate Cancer Progression: Prospects for Pharmacological Targeting”. KCC Joint Faculty Seminar Series, Thomas Jefferson University (October 26, 2009).
2010 “Curing Prostate Cancer”. Thomas Jefferson University: “A Celebration of Jefferson Women” (March 16, 2010).
2010 “Stat5 – Oncogene and Therapeutic Target in Prostate Cancer”. David M Davis Visiting Professor Seminar 2010: Eric Klein MD, Glickman Urological and Kidney Institute in Cleveland Clinic. Dept. of Urology, Thomas Jefferson University (June 17, 2010).
2010 “Stat5 Signaling Pathway in Prostate Cancer Progression and as a Therapeutic Target for Advanced Prostate Cancer”. 19th Meeting of European Association of Urological Research (ESUR). Vilnius, Lithuania (October 7-9, 2010).
2011 “Pharmacological Targeting of Stat5a/b Pathway in Advanced Prostate Cancer”, Urology Grand Rounds, Department of Urology, Thomas Jefferson University (April 7, 2011).
2012 “Targeting Prolactin Signaling in Prostate Cancer”, Annual Meeting of the Endocrine Society 2012. “Prolactin and Cancer”. Houston, TX (June 23-26, 2012).
2012 “Development of Stat5 Inhibitors for Prostate Cancer”, FASEB Summer Research Conference: The Growth Hormone/Prolactin Family in Biology and Disease (July 8-13, 2012).
2013 .”Therapeutic Targeting of Stat5 in castrate-resistant prostate cancer by pharmacological inhibitors of Jak2-Stat5 pathway”, Biomedicum, Univ. of Helsinki, Helsinki, Finland. March 4, 2013.
2013 .”Translating the Science of Prostate Cancer into Medicine”, The Prostate Net: Prostate Cancer Symposium, February 23, 2013, Philadelphia, PA.
2014 “Prolactin and Prostate Cancer: “Prl-Jak2-Stat5 Signaling Promotes Prostate Cancer Progression to Metastatic Castrate-Resistant Disease” GRS-IGF Society Meeting, Plenary Lecture, October 15-18, 2014, Singapore.
2014 “Stat5 in Promotion of Prostate Cancer Metastasis”, Sidney Kimmel Consortium Cancer Center at Jefferson 2014 Retreat and Poster Symposium, Thomas Jefferson University, Philadelphia, PA (October 1, 2014).
2014 “Stat5 inhibition in CRPC”. Amtrak Alliance Conference, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA (November 7, 2014).
2015 “Stat5 in Metastatic Progression of Prostate Cancer”. International Conference in Cytokine Signaling in Cancer. Plenary Lecture Invitation, May 24-29, 2015; Chania, Crete, Greece.
2015 "Jak-Stat5 Signaling in Progression of Prostate Cancer". October 28, 2015, Department of Pharmacology and Toxicology, Medical College of Wisconsin.
2015 “Stat5a/b in Prostate Cancer Metastases”. Pathology Grand Rounds, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA (January 12, 2015).
2015 “Jak2-Stat5 Signaling Promotes Prostate Cancer Progression”. Cancer Center at Medical College of Wisconsin, WI (January 28, 2015).
2015 "Therapeutic Targeting of Stat5 Signaling in Advanced Prostate Cancer", Cancer Center at the Medical College of Wisconsin, Cancer Cell Biology Program Research Forum, Milwaukee, Wisconsin. (November 12, 2015).
2015 Session Chair. FASEB meeting, The GH/Prl Family in Biology and Disease. Snowmass, Colorado. (2015)

PATENTS AND LICENSING AGREEMENTS:
2007 United States Patent 7,306,921. Diagnostic and Monitoring Methods for Cancer. Inventors: Nevalainen, MT, Rui, H. Filed Jan 2001. Issued, 2007.
2010 United States Patent 7,642,050. Method for predicting responsiveness of breast cancer to antiestrogen therapy. Inventors: Nevalainen, MT, Rui, H. Filed Jan 2001. Issued, 2010.
2012 US Provisional Patent Application, 2012. Office of Technology and Licensing, Thomas Jefferson University. Inventors; Marja T. Nevalainen, Zhiyong Liao. “Treatment of Hematological Neoplasms”, 37075-0290-P1-US, Pending (filed 8/15/2012).
2012 United States Patent 1212/548,383. US Provisional Patent Application, April 23, 2003. Converted to US Utility Patent Application, April 23, 2004; Office of Technology and Licensing, Georgetown University. Inventor; Marja T. Nevalainen. “Methods and Compositions for the Inhibition of Stat5 in Prostate Cancer Cells”. (RNA interference) 1212/548,383. Issued, 2012.
2012 US Provisional Patent Application, 2012. Offices of Technology and Licensing at Thomas Jefferson University and at Georgetown University. Inventors; Marja T. Nevalainen, Nagarajan Pattabiraman “Treatment of Prostate Cancer”, 37075-0259-P3-US, Pending (filed 8/15/2012).
2012 US Provisional Patent Application, 2012. Office of Technology and Licensing, Thomas Jefferson University. Inventors; Marja T. Nevalainen, Vincent Njar, Zhiyong Liao, Allen Reitz, Mark E McDonnell. “Treatment of Prostate Cancer and Hematological Neoplasms”, 37075-0282-P1-US, Pending (filed 8/15/2012).
2013 United States Patent 13/477,923. US Provisional Patent Application, May 22, 2012. Office of Technology and Licensing, Georgetown University. Inventor; Marja T. Nevalainen. “Methods and Compositions for the Inhibition of Stat5 in Prostate Cancer Cells”. (Antibodies and small molecules) 13/477,923. Issued, Nov. 14, 2013.
Scripps Research Institute; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
Vanderbilt University; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
Schering-Plough; Licensing Agreement: CWR22Pc Prostate Cancer Cell line (Developed in the Nevalainen Laboratory).
Daiichi-Sankyo; Licensing Agreement: CWR22Pc Prostate Cancer Cell line (Developed in the Nevalainen Laboratory).
Bayer; Licensing Agreement: CWR22Pc Prostate Cancer Cell line (Developed in the Nevalainen Laboratory).
Howard Hughes Medical Institute; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
Memorial Sloan Kettering Cancer Center; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
Wayne State University; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
University of Tampere, Finland; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
Dana Farber Cancer Institute; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
Umea University, Sweden; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
Hoffman La-Roche, Inc.; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
Astra Zeneca UK; Licensing Agreement: CWR22Pc Prostate Cancer Cell line (Developed in the Nevalainen Laboratory).
University of California-Davis; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
University of South Florida; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
University of California-Riverside; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
Roswell Park Cancer Institute; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
John Hopkins Medical Institutions; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
Innsbruck Medical University; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
Burnham Institute for Medical Research; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
National Cancer Institute; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
Astra Zeneca, USA; Licensing Agreement: CWR22Pc Prostate Cancer Cell line (Developed in the Nevalainen Laboratory).
Celgene; Licensing Agreement: CWR22Pc Prostate Cancer Cell line (Developed in the Nevalainen Laboratory).
University of Michigan; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
New York University Medical Center; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
University of Helsinki; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
University of Pennsylvania; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
Biotech Research and Innovation Center, Denmark; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
Louisiana State University ; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
University of Minnesota; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).
University of Wisconsin - Madison; Licensing Agreement: CWR22Pc Cell line (Developed in the Nevalainen Laboratory).

REVIEWER (GRANTS):
2004 Georgetown University, Intramural Research Grants program. (2004)
2004 Welcome Trust Fund. (August 3, 2004)
2004 Israel Science Foundation (ISF). (April 1, 2004)
2005 Austrian Science Foundation, START-prize grant review. (March 7, 2005)
2006 National Institutes of Health, Special Emphasis Panel/Scientific Review Group 2006 ZCA1 RPRB-G NCI, Loan Repayment Program for Clinical Research, L30 and Pediatric Research. (2006)
2006 Review Panel for the American Cancer Society Research Scholar Grant, Molecular Genetics and Oncogenesis Study Section. (June 27-28, 2006)
2006 Integration Panel Reviewer for Congressionally Directed Medical Research Programs of Department of Defense: Prostate Cancer Program Programmatic Review, Virginia. (October 2-4, 2006)
2007 - 2011 Review Panel for the American Cancer Society Research Scholar Grant, Molecular Genetics and Oncogenesis Study Section. Atlanta, GA. Standing member of the review panel.
2007 Integration Panel for the Congressionally Directed Medical Research Programs of Department of Defense: Prostate Cancer Program Programmatic Review, Virginia. (October 9-10, 2007)
2008 National Institutes of Health, Special Emphasis Panel/Scientific Review Group 2008 ZCA1 RPRB-G NCI, Loan Repayment Program for Clinical Research, L30 and Pediatric Research. (2008)
2008 Integration Panel for the Congressionally Directed Medical Research Programs of Department of Defense: Prostate Cancer Program Programmatic Review, Virginia. (November, 6-7, 2008)
2008 American Cancer Society Research Scholar Grant Review Panel, Molecular Genetics and Oncogenesis Study Section. Atlanta, GA. (January 23-24, 2008)
2009 American Cancer Society Research Scholar Grant Review Panel, Molecular Genetics and Oncogenesis Study Section. Atlanta, GA. (June 23-24, 2009)
2010 American Cancer Society Research Scholar Grant Review Panel, Molecular Genetics and Oncogenesis Study Section. Atlanta, GA. (January 26-27, 2010)
2010 Integration Panel for the Congressionally Directed Medical Research Programs of Department of Defense: Prostate Cancer Research Program Programmatic Review, Virginia. (October 13-14, 2010)
2011 American Cancer Society Research Scholar Grant Review Panel, Molecular Genetics and Oncogenesis Study Section. Atlanta, GA. (January 22-23, 2011)
2012 National Institutes of Health, Special Emphasis Panel/Scientific Review Group 2012 ZRG1 FO9-A Study Section; Basic, Translational and Clinical Oncology. (2012)
2013 National Institutes of Health, Cancer Molecular Pathobiology (CAMP), Oncological Basic and Translational IRG. (February 13-15, 2013)
2015 Integration Panel for the Cancer Research Program Programmatic Review.(July 30, 2015)
2015 Integration Panel for the Congressionally Directed Medical Research Programs of Department of Defense: Prostate Cancer Research Program Programmatic Review, Washington DC. (January 27-28, 2015)
2016 Invited-Integration Panel for the Congressionally Directed Medical Research Programs of Department of Defense: Prostate Cancer Research Program Programmatic Review, Washington, DC.
2017 Grant reviewer for Department of Defense Prostate Cancer Research Program, pre-applications. August 2017

SUPPORT (ACTIVE):
2012 - 2017 Principal Investigator (Nevalainen), NIH (NCI) RO1-Grant (2RO1CA113580-06) (07/2012-06/2017): “Stat5 in Progression of Prostate Cancer”, NCI, Initial Funding (TCB Study Section, Scored 12th percentile) 2006-2011. Competitive Renewal Application 2011: TCB Study Section, Scored 3rd percentile (competitive renewal 07/2012-06/2017).
2012 - 2016 Subcontract, Co-Investigator (Nevalainen), Principal Investigator: Scott Dehm, University of Minnesota. "AR Gene Rearrangements and Androgen Receptor Signaling in Prostate Cancer". NCI/NIH (5RO1CA174777). Funded (Subcontract $9,000).
2013 - 2018 Co-Investigator, (Nevalainen, 2% support), Principal Investigator (Bruno Calabretta), Thomas Jefferson University. Targeting C/EBPalpha/Gif – pathway in CML stem cells. NIH/NCI RO1 (CA167169-01A1) (2013-2018).
2013 - 2016 Principal Investigator (Nevalainen): NIH (NCI) R21 (1R21CA178755-01): “Novel strategy to sensitize prostate cancer cells to radiation”, $412,500 ($275,000), (2013-2016). Received fundable score for the first submission of the grant in a study section review (Feb 27, 2013): 9.0 percentile, priority score 23. Funded (July 2013).
2013 - 2017 Mentor (Nevalainen), MD-PhD-student (Hoang, David): NCI F31 NRSA Pre-doctoral Fellowship (1F31CA180626-01): Title: Stat5 acts independently of androgen receptor to drive advanced prostate cancer. Impact Score/Percentile: 19/8.0. Funded Aug. 2013.
2015 - 2020 Co-Investigator (Nevalainen, 10% support), Principal Investigator (Hallgeir Rui) NIH R01CA188575 (5 year: 04.01. 2015 - 03.31. 2020). “Prolactin pathways and metastatic progression of ER-positive breast cancer”
07/01/2017 - 06/30/2021 PI, (Nevalainen 20%), NIH/NCI R01 - Grant (2R01CA113580-06): "Stat 5 in Progression of Prostate Cancer", Competitive Renewal Application. Pending A0.

SUPPORT (COMPLETED):
2001 - 2002 Collaborator, NIH U54 CA100970-01, PI; Leena Hilakivi-Clarke.
2004 - 2008 Principal Investigator: New Investigator Award; “Stat5 a Therapeutic Target Protein for Prostate Cancer”, Department of Defense Prostate Cancer Research Program (2004-2008). $349,200 ($75,000/yr direct).
2004 - 2014 Principal Investigator: Research Award for Prostate Cancer Research; “Stat5 as a Critical Survival Factor in Prostate Cancer”, American Cancer Society, Individual Allocation from an Institutional Research Grant, IRG 97-152-11, (01/01/2004 – 12/31/2014).
2004 - 2008 Principal Investigator, Research Scholar Grant;“Androgen-Independent Growth Signaling Pathways in Prostate Cancer”, American Cancer Society (2004 – 2008). Score 1 percentile in Molecular Genetics and Oncogenes (MGO) Study Section. $960,000 ($200,000/yr direct).
2004 - 2007 Principal Investigator, Investigator Initiated Grant; “Lipid Modulation of Jak2-Stat5 Signal Transduction Pathway in Prostate Cancer”, American Institute for Cancer Research (2004 – 2007). $165,000 ($75,000/yr direct).
2004 - 2005 Principal Investigator: Lombardi Comprehensive Cancer Center Developmental Funds, “Jak2 - Stat5 Signaling in Prostate Cancer”.
2006 - 2009 Principal Investigator: Idea Development Award; “Stat3 in Metastatic Progression of Prostate Cancer”, Department of Defense Prostate Cancer Research Program (2006-2009). $582,000 ($125,000/yr direct).
2007 - 2010 Principal Investigator: Idea Development Award; “Interaction of Transcription Factor Stat5 with Androgen Receptor in Growth Promotion of Prostate Cancer”, Department of Defense Prostate Cancer Research Program (2007-2010). $582,000 ($125,000/yr direct).
2008 - 2010 Co-PI: American Cancer Society Institutional Research Grant (IRG-114958), Thomas Jefferson University; Kimmel Cancer Center; (PI: Richard Pestell), (2008-2010). $210,000 ($70,000/yr direct).
2009 - 2011 Principal Investigator: Sponsored Research Contract Astra Zeneca; “Therapeutic Targeting of Stat5 and Stat3 in Human Prostate Cancer by AZD1480”; (2009-2011). Total $384,000 ($166,000/yr direct).
2010 - 2015 Co-Principal Investigator (Nevalainen): American Cancer Society Institutional Research Grant (IRG-114958), Thomas Jefferson University; Kimmel Cancer Center; (PI: Richard Pestell), (2010-2015). $480,000.
2011 - 2014 Principal Investigator (Nevalainen): Sponsored Research Contract Novartis; “Therapeutic Targeting of Stat5 in Human Prostate Cancer by LFA102 – Prolactin Receptor Antagonist and Ruxolitinib (Jak2-inhibitor); (2011-July 2014). Total $895,872 ($200,869/yr direct).
2013 - 2014 Principal Investigator (Nevalainen): Dean’s Support for Programmatic Research Initiatives, Thomas Jefferson University: Stat5 in Cancer Therapy. (Co-PI: Bruno Calabretta). (2013- 2014) ($50,000).
2014 - 2015 Principal Investigator (Nevalainen), Co-PI (Allessandro Fatatis): SKCC: TJU-Drexel Support for Collaborative Initiatives: Stat5 in Prostate Cancer Metastasis. ($20,000).

SUPPORT (PENDING):
Multi-PI R01 (NIH//NCI) Consortium (Contact PI: Nevalainen; Multi-PI, Vincent Njar, University of Maryland; Co-Investigators: Bruno Calabretta, Thomas Jefferson University; Nagarajan Pattabiraman, MOLBox LLC; John Imig, MCW. Collaborators: Brian Volkman, MCW; Brian Smith, MCW; Nancy Dahms, MCW; Purushottam Laud, MCW; William See, MCW; Ken Iczkowski, MCW). "Lead Optimization and Development of Novel Stat5a/b Inhibitors for Prostate Cancer And Leukemia Therapy". Pending A0.

TEACHING ACTIVITIES:
2002 Georgetown University, Washington DC, Medical School Lecture: Gross Anatomy, dissections of cadavers (September, 2002); MD-students: Abdomen, Pelvis 9 x 3 h
2004 Georgetown University, Washington DC, Graduate Student Lecture: Lecture (Tumor Biology I: Molecular Basis of the Transformed Cell): “Prostate Cancer” (November 23, 2004). Scored 4.4 by the student on scale 1-5 where 5 is the best.
2004 Georgetown University, Washington DC, Graduate Student Lecture: Brown Bag Seminar Series, “Therapy Development for Prostate Cancer”, Lombardi Comprehensive Cancer Center, Georgetown University. (July 14, 2004)
2005 Georgetown University, Washington DC, Graduate Student Lecture: Lecture Tumor Biology I: PhD-graduate program (Growth Regulation of Cancer) (March 24, 2005): “Stat3 dimerization regulated by reversible acetylation of a single lysine”.
2005 Georgetown University, Washington DC, Medical School Lecture: Lecture (Dept. of Cell Biology: Microscopic Anatomy; MD-students): “Thyroid/Parathyroid” (November 29, 2005). Scored 3.8 by the students on the scale 1-5 where 5 is the best.
2005 Georgetown University, Washington DC, Medical School Lecture: Microscopy Presentation (Dept. of Cell Biology, Microscopic Anatomy; MD-students): “Thyroid/Parathyroid Gland, Adrenal Gland”, (November 30, 2005). Scored 3.8 by the students on the scale 1-5 where 5 is the best.
2005 Georgetown University, Washington DC, Medical School Lecture: Microscopic Anatomy Exam, December 12, 2005
2005 Georgetown University, Washington DC, Medical School Lecture: Microscopy Presentation (Dept. of Cell Biology: Microscopic Anatomy; MD-students): “Thyroid/Parathyroid Gland, Adrenal Gland”, (December 5, 2005). Scored 3.8 by the students on the scale 1-5 where 5 is the best.
2006 Thomas Jefferson University, Graduate Student Lecture: Cell Cycle Regulation Course (GE636) – Role of STAT proteins in proliferation, survival and transcription, (2h)
2006 Thomas Jefferson University, Graduate Student Lecture: Molecular Genetics (GE652) – Molecular Basis of Cancer, Transcription Factor Stat5 in Growth of Prostate Cancer, (2h)
2007 Thomas Jefferson University, Graduate Student Lecture: Cell Cycle Regulation Course (GE636) –Role of STAT proteins in proliferation, survival and transcription, (2h)
2007 Thomas Jefferson University, Graduate Student Lecture: Molecular Genetics (GE652) – Molecular Basis of Cancer, Transcription Factor Stat5 in Growth of Prostate Cancer, (2h)
2008 Thomas Jefferson University, Graduate Student Lecture: Molecular Genetics (GE652) – Molecular Basis of Cancer, Transcription Factor Stat5 in Growth of Prostate Cancer, (2h)
2008 Thomas Jefferson University, Graduate Student Lecture: Cell Cycle Regulation Course (GE636)– Role of STAT proteins in proliferation, survival and transcription, (2h) (Calabretta, Course Director)
2009 Thomas Jefferson University, Graduate Student Lecture: Molecular Basis of Cancer (GE652) – Stat Proteins in Cancer, (2h) (Buchberg, Course Director)
2009 Thomas Jefferson University, Graduate Student Lecture: Cell Cycle Regulation Course – Role of STAT proteins in proliferation, survival and transcription, (2h) (Calabretta, Course Director)
2010 Thomas Jefferson University, Graduate Student Lecture: Molecular Basis of Cancer (GE652) – Stat Proteins in Cancer, (2h) (Buchberg, Course Director)
2010 Thomas Jefferson University, Graduate Student Lecture: Cell Cycle Regulation Course – Role of STAT proteins in proliferation, survival and transcription, (2h) (Calabretta, Course Director)
2011 Thomas Jefferson University, Graduate Student Lecture: Cell Cycle Regulation Course – Role of STAT proteins in proliferation, survival and transcription, (2h) (Calabretta, Course Director)
2011 - 2015 Thomas Jefferson University, GE652 Molecular Basis of Cancer (Nevalainen, Course Director).
2011 Thomas Jefferson University, Graduate Student Lecture: Molecular Basis of Cancer (GE652) – Stat Proteins in Cancer, (2h) (Buchberg, Course Director)
2012 Thomas Jefferson University, Graduate Student Lecture: Cell Cycle Regulation Course – Role of STAT proteins in proliferation, survival and transcription, (2h) (Calabretta, Course Director)
2013 Thomas Jefferson University, Graduate Student Lecture: Cell Cycle Regulation Course – Role of STAT proteins in proliferation, survival and transcription, (2h) (Calabretta, Course Director)
2014 Thomas Jefferson University, Graduate Student Lecture: Cell Cycle Regulation Course – Role of STAT proteins in proliferation, survival and transcription, (2h) (Calabretta, Course Director)

VOLUNTEER, COMMUNITY AND INSTITUTIONAL SERVICE:
2004 - ACS Community Awareness Meeting, presentation "Where the Money Goes" to Laurel High School, Maryland.
2004 - Present Volunteer for the American Cancer Society in public education.
2006 - 2010 At Thomas Jefferson University, served on Committee on Research.
2007 - At Thomas Jefferson University, Sidney Kimmel Cancer Center; served in the preparation, writing and submission of Application for Institutional Research Grant to American Cancer Society. Funded 2007.
2007 - 2015 At Thomas Jefferson University, served on the Sidney Kimmel Cancer Center Training Committee, and served as Chair.
2007 - 2015 At Thomas Jefferson University, served on the Executive Committee for the Sidney Kimmel Cancer Center.
2007 - At Thomas Jefferson University, served as Judge for the Sigma Xi Research Day.
2007 - 2015 At Thomas Jefferson University, served on the Sidney Kimmel Cancer Center Small-Molecule Screening Facility Committee.
2008 - At Thomas Jefferson University, served as Judge on Sigma Xi Research Day.
2008 - 2010 At Thomas Jefferson University, served on the Sidney Kimmel Cancer Center Seminar Committee
2009 - 2010 At Thomas Jefferson University, served as a member of the Research Advisory Committee.
2010 - At Thomas Jefferson University, Sidney Kimmel Cancer Center and Nemours and Helen Graham Cancer Center, served in the preparation, writing and submission of Application for Institutional Research Grant to American Cancer Society, Consortium with Univ. of Delaware, LIMR. Funded 2010.
2011 - 2015 At Thomas Jefferson University, served as a member of the Dean's Research Leaders Council.
2012 - 2013 At Thomas Jefferson University, served as a member of the Faculty Senate.


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Nevalainen MT, Valve EM, Mäkelä SI, Bläuer M, Tuohimaa PJ, Härkönen PL. Estrogen and prolactin regulation of rat dorsal and lateral prostate in organ culture. Endocrinology. 1991 Aug;129(2):612-22.
2. Nevalainen MT, Härkönen PL, Valve EM, Ping W, Nurmi M, Martikainen PM. Hormone regulation of human prostate in organ culture. Cancer Res. 1993 Nov 01;53(21):5199-207.
3. Nevalainen MT, Valve EM, Ingleton PM, Härkönen PL. Expression and hormone regulation of prolactin receptors in rat dorsal and lateral prostate. Endocrinology. 1996 Jul;137(7):3078-88.
4. Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, Harkonen PL. Prolactin and prolactin receptors are expressed and functioning in human prostate. J Clin Invest. 1997 Feb 15;99(4):618-27. PMCID: PMC507843
5. Nevalainen MT, Valve EM, Ahonen T, Yagi A, Paranko J, Härkönen PL. Androgen-dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture. FASEB J. 1997 Dec;11(14):1297-307.
6. Kallajoki M, Alanen KA, Nevalainen MT, Nurmi M, Nevalainen TJ Expression of Group II Phospholipase A2 in Male Reproductive Organs and Male Genital Tumors. Prostate. 35:263-272, 1998
7. Ahonen TJ, Härkönen PL, Laine J, Rui H, Martikainen PM, Nevalainen MT. Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology. 1999 Nov;140(11):5412-21.
8. Nevalainen MT, Ahonen TJ, Yamashita H, Chandrashekar V, Bartke A, Grimley PM, Robinson GW, Hennighausen L, Rui H. Epithelial defect in prostates of Stat5a-null mice. Lab Invest. 2000 Jul;80(7):993-1006.
9. Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Härkönen P. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res. 2001 Feb;29(1):23-8.
10. Valve EM, Nevalainen MT, Nurmi MJ, Laato MK, Martikainen PM, Härkönen PL. Increased expression of FGF-8 isoforms and FGF receptors in human premalignant prostatic intraepithelial neoplasia lesions and prostate cancer. Lab Invest. 2001 Jun;81(6):815-26.
11. Yamashita H, Nevalainen MT, Xu J, LeBaron MJ, Wagner KU, Erwin RA, Harmon JM, Hennighausen L, Kirken RA, Rui H. Role of serine phosphorylation of Stat5a in prolactin-stimulated beta-casein gene expression. Mol Cell Endocrinol. 2001 Oct 25;183(1-2):151-63.
12. Ahonen TJ, Härkönen PL, Rui H, Nevalainen MT. PRL signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro. Endocrinology. 2002 Jan;143(1):228-38.
13. Xie J, LeBaron MJ, Nevalainen MT, Rui H. Role of tyrosine kinase Jak2 in prolactin-induced differentiation and growth of mammary epithelial cells. J Biol Chem. 2002 Apr 19;277(16):14020-30.
14. Nevalainen MT, Xie J, Bubendorf L, Wagner KU, Rui H. Basal activation of transcription factor signal transducer and activator of transcription (Stat5) in nonpregnant mouse and human breast epithelium. Mol Endocrinol. 2002 May;16(5):1108-24.
15. Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K, Rui H, Nevalainen MT. Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem. 2003 Jul 18;278(29):27287-92.
16. Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J, Sauter G, Rui H. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol. 2004 Jun 01;22(11):2053-60.
17. Li H, Ahonen TJ, Alanen K, Xie J, LeBaron MJ, Pretlow TG, Ealley EL, Zhang Y, Nurmi M, Singh B, Martikainen PM, Nevalainen MT. Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res. 2004 Jul 15;64(14):4774-82.
18. Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H. Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene. 2005 Jan 27;24(5):746-60.
19. Li H, Zhang Y, Glass A, Zellweger T, Gehan E, Bubendorf L, Gelmann EP, Nevalainen MT. Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res. 2005 Aug 15;11(16):5863-8.
20. Popov VM, Wang C, Shirley LA, Rosenberg A, Li S, Nevalainen M, Fu M, Pestell RG. The functional significance of nuclear receptor acetylation. Steroids. 2007 Feb;72(2):221-30. PMCID: PMC2694494
21. LeBaron MJ, Ahonen TJ, Nevalainen MT, Rui H. In vivo response-based identification of direct hormone target cell populations using high-density tissue arrays. Endocrinology. 2007 Mar;148(3):989-1008.
22. Dagvadorj A, Collins S, Jomain JB, Abdulghani J, Karras J, Zellweger T, Li H, Nurmi M, Alanen K, Mirtti T, Visakorpi T, Bubendorf L, Goffin V, Nevalainen MT. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology. 2007 Jul;148(7):3089-101.
23. Tan SH, Dagvadorj A, Shen F, Gu L, Liao Z, Abdulghani J, Zhang Y, Gelmann EP, Zellweger T, Culig Z, Visakorpi T, Bubendorf L, Kirken RA, Karras J, Nevalainen MT. Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res. 2008 Jan 01;68(1):236-48.
24. Dagvadorj A, Kirken RA, Leiby B, Karras J, Nevalainen MT. Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo. Clin Cancer Res. 2008 Mar 01;14(5):1317-24.
25. Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Zellweger T, Alanen K, Mirtti T, Visakorpi T, Bubendorf L, Nevalainen MT. Stat3 promotes metastatic progression of prostate cancer. Am J Pathol. 2008 Jun;172(6):1717-28. PMCID: PMC2408430
26. Tan SH, Nevalainen MT. Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocr Relat Cancer. 2008 Jun;15(2):367-90. PMCID: PMC6036917
27. Dagvadorj A, Tan SH, Liao Z, Cavalli LR, Haddad BR, Nevalainen MT. Androgen-regulated and highly tumorigenic human prostate cancer cell line established from a transplantable primary CWR22 tumor. Clin Cancer Res. 2008 Oct 01;14(19):6062-72. PMCID: PMC2570751
28. Liao Z, Lutz J, Nevalainen MT. Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer. Int J Biochem Cell Biol. 2010 Feb;42(2):186-92. PMCID: PMC2818495
29. Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Addya S, Fortina P, Dasgupta A, Hyslop T, Bubendorf L, Nevalainen MT. Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth. Am J Pathol. 2010 Apr;176(4):1959-72. PMCID: PMC2843484
30. Reddy A, Huang CC, Liu H, Delisi C, Nevalainen MT, Szalma S, Bhanot G. Robust gene network analysis reveals alteration of the STAT5a network as a hallmark of prostate cancer. Genome Inform. 2010;24:139-53. PMCID: PMC6035043
31. Gu L, Zhu XH, Visakorpi T, Alanen K, Mirtti T, Edmonston TB, Nevalainen MT. Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer. Anal Cell Pathol (Amst). 2010;33(2):55-9. PMCID: PMC4605774
32. Gu L, Vogiatzi P, Puhr M, Dagvadorj A, Lutz J, Ryder A, Addya S, Fortina P, Cooper C, Leiby B, Dasgupta A, Hyslop T, Bubendorf L, Alanen K, Mirtti T, Nevalainen MT. Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer. 2010 Jun;17(2):481-93. PMCID: PMC6260789
33. Dagvadorj A, Tan SH, Liao Z, Xie J, Nurmi M, Alanen K, Rui H, Mirtti T, Nevalainen MT. N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells. Int J Biochem Cell Biol. 2010 Dec;42(12):2037-46. PMCID: PMC2982800
34. Sato T, Neilson LM, Peck AR, Liu C, Tran TH, Witkiewicz A, Hyslop T, Nevalainen MT, Sauter G, Rui H. Signal transducer and activator of transcription-3 and breast cancer prognosis. Am J Cancer Res. 2011;1(3):347-55. PMCID: PMC3138712
35. Liao Z, Nevalainen MT. Targeting transcription factor Stat5a/b as a therapeutic strategy for prostate cancer. Am J Transl Res. 2011 Feb;3(2):133-8. PMCID: PMC3056559
36. Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E, Freydin B, Tran TH, Yang N, Rosenberg AL, Hooke JA, Kovatich AJ, Nevalainen MT, Shriver CD, Hyslop T, Sauter G, Rimm DL, Magliocco AM, Rui H. Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol. 2011 Jun 20;29(18):2448-58. PMCID: PMC3675698
37. Koptyra M, Gupta S, Talati P, Nevalainen MT. Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancer. Int J Biochem Cell Biol. 2011 Oct;43(10):1417-21. PMCID: PMC3163765
38. Stankiewicz TR, Loucks FA, Schroeder EK, Nevalainen MT, Tyler KL, Aktories K, Bouchard RJ, Linseman DA. Signal transducer and activator of transcription-5 mediates neuronal apoptosis induced by inhibition of Rac GTPase activity. J Biol Chem. 2012 May 11;287(20):16835-48. PMCID: PMC3351344
39. Goffin V, Hoang DT, Bogorad RL, Nevalainen MT. Prolactin regulation of the prostate gland: a female player in a male game. Nat Rev Urol. 2011 Oct 04;8(11):597-607. PMCID: PMC6035044
40. Mirtti T, Leiby BE, Abdulghani J, Aaltonen E, Pavela M, Mamtani A, Alanen K, Egevad L, Granfors T, Josefsson A, Stattin P, Bergh A, Nevalainen MT. Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy. Hum Pathol. 2013 Mar;44(3):310-9. PMCID: PMC3548055
41. Haddad BR, Gu L, Mirtti T, Dagvadorj A, Vogiatzi P, Hoang DT, Bajaj R, Leiby B, Ellsworth E, Blackmon S, Ruiz C, Curtis M, Fortina P, Ertel A, Liu C, Rui H, Visakorpi T, Bubendorf L, Lallas CD, Trabulsi EJ, McCue P, Gomella L, Nevalainen MT. STAT5A/B gene locus undergoes amplification during human prostate cancer progression. Am J Pathol. 2013 Jun;182(6):2264-75. PMCID: PMC3668029
42. Gu L, Liao Z, Hoang DT, Dagvadorj A, Gupta S, Blackmon S, Ellsworth E, Talati P, Leiby B, Zinda M, Lallas CD, Trabulsi EJ, McCue P, Gomella L, Huszar D, Nevalainen MT. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer. Clin Cancer Res. 2013 Oct 15;19(20):5658-74. PMCID: PMC6021137
43. Gu L, Talati P, Vogiatzi P, Romero-Weaver AL, Abdulghani J, Liao Z, Leiby B, Hoang DT, Mirtti T, Alanen K, Zinda M, Huszar D, Nevalainen MT. Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. Mol Cancer Ther. 2014 May;13(5):1246-58. PMCID: PMC4013199
44. Hoang DT, Gu L, Liao Z, Shen F, Talati PG, Koptyra M, Tan SH, Ellsworth E, Gupta S, Montie H, Dagvadorj A, Savolainen S, Leiby B, Mirtti T, Merry DE, Nevalainen MT. Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer. Mol Cancer Ther. 2015 Mar;14(3):713-26. PMCID: PMC4456253
45. Liao Z, Gu L, Vergalli J, Mariani SA, De Dominici M, Lokareddy RK, Dagvadorj A, Purushottamachar P, McCue PA, Trabulsi E, Lallas CD, Gupta S, Ellsworth E, Blackmon S, Ertel A, Fortina P, Leiby B, Xia G, Rui H, Hoang DT, Gomella LG, Cingolani G, Njar V, Pattabiraman N, Calabretta B, Nevalainen MT. Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia. Mol Cancer Ther. 2015 Aug;14(8):1777-93. PMCID: PMC4547362
46. Talati PG, Gu L, Ellsworth EM, Girondo MA, Trerotola M, Hoang DT, Leiby B, Dagvadorj A, McCue PA, Lallas CD, Trabulsi EJ, Gomella L, Aplin AE, Languino L, Fatatis A, Rui H, Nevalainen MT. Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer. Am J Pathol. 2015 Sep;185(9):2505-22. PMCID: PMC4597281
47. Li G, Hayward IN, Jenkins BR, Rothfuss HM, Young CH, Nevalainen MT, Muth A, Thompson PR, Navratil AM, Cherrington BD. Peptidylarginine Deiminase 3 (PAD3) Is Upregulated by Prolactin Stimulation of CID-9 Cells and Expressed in the Lactating Mouse Mammary Gland. PLoS One. 2016;11(1):e0147503. PMCID: PMC4723263
48. Singh A, Fedele C, Lu H, Nevalainen MT, Keen JH, Languino LR. Exosome-mediated Transfer of αvβ3 Integrin from Tumorigenic to Nontumorigenic Cells Promotes a Migratory Phenotype. Mol Cancer Res. 2016 11;14(11):1136-1146. PMCID: PMC5107121
49. Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. Oncotarget. 2017 Jan 10;8(2):3724-3745. PMCID: PMC5356914
50. Wang Y, Lieberman R, Pan J, Zhang Q, Du M, Zhang P, Nevalainen M, Kohli M, Shenoy NK, Meng H, You M, Wang L. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Mol Cancer. 2016 11 10;15(1):70. PMCID: PMC5105253
51. Sreenath TL, Macalindong SS, Mikhalkevich N, Sharad S, Mohamed A, Young D, Borbiev T, Xavier C, Gupta R, Jamal M, Babcock K, Tan SH, Nevalainen MT, Dobi A, Petrovics G, Sesterhenn IA, Rosner IL, Bieberich CJ, Nelson P, Vasioukhin V, Srivastava S. ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development. Sci Rep. 2017 04 24;7(1):1109. PMCID: PMC5430720
52. Sreenath TL, Macalindong SS, Mikhalkevich N, Sharad S, Mohamed A, Young D, Borbiev T, Xavier C, Gupta R, Jamal M, Babcock K, Tan SH, Nevalainen MT, Dobi A, Petrovics G, Sesterhenn IA, Rosner IL, Bieberich CJ, Nelson P, Vasioukhin V, Srivastava S. Erratum: ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development. Sci Rep. 2017 09 06;7(1):10693. PMCID: PMC5587674
53. Hurrell SL, McGarry SD, Kaczmarowski A, Iczkowski KA, Jacobsohn K, Hohenwalter MD, Hall WA, See WA, Banerjee A, Charles DK, Nevalainen MT, Mackinnon AC, LaViolette PS. Optimized -value selection for the discrimination of prostate cancer grades, including the cribriform pattern, using diffusion weighted imaging. J Med Imaging (Bellingham). 2018 01;5(1):011004. PMCID: PMC5658575
54. Maranto C, Udhane V, Hoang DT, Gu L, Alexeev V, Malas K, Cardenas K, Brody JR, Rodeck U, Bergom C, Iczkowski KA, Jacobsohn K, See W, Schmitt SM, Nevalainen MT. “Stat5a/b Inhibition Sensitizes Prostate Cancer to Radiation through Inhibition of Rad51 and DNA Repair”. In Press. Clinical Cancer Res, Jan. 2018.
55. Maranto C, Udhane V, Hoang DT, Gu L, Alexeev V, Malas K, Cardenas K, Brody JR, Rodeck U, Bergom C, Iczkowski KA, Jacobsohn K, See W, Schmitt SM, Nevalainen MT. STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair. Clin Cancer Res. 2018 04 15;24(8):1917-1931. PMCID: PMC6036914
56. McGarry SD, Hurrell SL, Iczkowski KA, Hall W, Kaczmarowski AL, Banerjee A, Keuter T, Jacobsohn K, Bukowy JD, Nevalainen MT, Hohenwalter MD, See WA, LaViolette PS. Radio-pathomic Maps of Epithelium and Lumen Density Predict the Location of High-Grade Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 08 01;101(5):1179-1187. PMCID: PMC6190585
57. Minieri V, De Dominici M, Porazzi P, Mariani SA, Spinelli O, Rambaldi A, Peterson LF, Porcu P, Nevalainen MT, Calabretta B. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia. Cancer Res. 2018 10 15;78(20):5793-5807.
58. Minieri V, De Dominici M, Nevalainen MT, Calabretta B. Targeting the STAT5 pathway in Ph+ acute lymphoblastic leukemia. Oncotarget. 2018 Dec 04;9(95):36726-36727. PMCID: PMC6298402
59. McGarry SD, Bukowy JD, Iczkowski KA, Unteriner JG, Duvnjak P, Lowman AK, Jacobsohn K, Hohenwalter M, Griffin MO, Barrington AW, Foss HE, Keuter T, Hurrell SL, See WA, Nevalainen MT, Banerjee A, LaViolette PS. Gleason Probability Maps: A Radiomics Tool for Mapping Prostate Cancer Likelihood in MRI Space. Tomography. 2019 03;5(1):127-134. PMCID: PMC6403022
60. Haddad BR, Erickson A, Udhane V, LaViolette PS, Rone JD, Kallajoki MA, See WA, Rannikko A, Mirtti T, Nevalainen MT. Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1642-1651. PMCID: PMC6774884
61. Nevalainen M, Gupta S. Jak2/Stat5a/b pathway in prostate cancer Cancer Therapeutic Targets. 1 January 2017;2-2:745-752.
62. Mirtti TK, Talati P, Nevalainen MT. Transcription factors Stat5a/b and Stat3 in prostate cancer growth and metastases Signaling Pathways and Molecular Mediators in Metastasis. 1 January 2014:245-260.
63. Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot EC, Freydin BC, Tran TH, Yang N, Rosenberg AL, Hooke JA, Kovatich AJ, Nevalainen MT, Shriver CD, Hyslop T, Sauter G, Rimm DL, Magliocco AM, Rui H. Reply to A. Italiano Journal of Clinical Oncology. 10 December 2011;29(35):4718-4719.
64. Liao Z, Nevalainen MT. Targeting transcription factor stat5a/b as a therapeutic strategy for prostate cancer American Journal of Translational Research. 2011;3(2):133-138.
65. Rui H, Nevalainen MT. Prolactin The Cytokine Handbook. July 07, 2003:115-147.
66. Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K, Rui H, Nevalainen MT. Erratum: Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells (Journal of Biological Chemistry (2003) 278 (27287-27292)) Journal of Biological Chemistry. 3 October 2003;278(40):39259.
67. Udhane V, Maranto C, Hoang DT, Gu L, Erickson A, Devi S, Talati PG, Banerjee A, Iczkowski KA, Jacobsohn K, See WA, Mirtti T, Kilari D, Nevalainen MT. Enzalutamide Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors. Mol Cancer Ther. 2019 Sep 23.
 

jenkins-FCD Prod-410 e9586552fe7f53c71f7923aa6e27aeabbd3c2473